Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2011-04-25

Last Posted Date: 2011-04-25

Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Target Recruit Count: 378

Registration Number: NCT01341262

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2011-04-14

Last Posted Date: 2018-01-23

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 61

Registration Number: NCT01335685

Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)

Phase 1

Completed

Conditions: Myeloma

First Posted Date: 2011-01-19

Last Posted Date: 2016-04-13

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 72

Registration Number: NCT01279694

Locations: 🇫🇷
CHU de Nantes, Nantes, France

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date: 2010-12-08

Last Posted Date: 2023-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT01256398

Locations: 🇺🇸
Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
🇺🇸
Longmont United Hospital, Longmont, Colorado, United States

and more 98 locations

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Withdrawn

Conditions: DS Stage I Plasma Cell Myeloma
Refractory Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Gamma-Secretase Inhibitor RO4929097
Procedure: Hematopoietic Stem Cell Mobilization
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Melphalan

First Posted Date: 2010-12-01

Last Posted Date: 2017-09-28

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01251172

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Phase 2

Completed

Conditions: Myeloma

Interventions: Drug: Palifermin
Drug: Dexamethasone
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Procedure: Stem Cell Transplant
Drug: G-CSF

First Posted Date: 2010-11-10

Last Posted Date: 2020-05-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT01237951

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Revlimid
Drug: Melphalan
Drug: Dexamethasone
Drug: Prednisone
Drug: Velcade

First Posted Date: 2010-11-09

Last Posted Date: 2017-01-18

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 250

Registration Number: NCT01237249

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital Clínico de Valencia., Valencia, Spain

and more 60 locations

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Procedure: Stem Cell Transplantation
Drug: Palifermin

First Posted Date: 2010-09-13

Last Posted Date: 2019-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 81

Registration Number: NCT01200329

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Phase 1

Active, not recruiting

Conditions: Regional Neuroblastoma
Ganglioneuroblastoma
Localized Unresectable Neuroblastoma
Stage 4 Neuroblastoma
Localized Resectable Neuroblastoma
Stage 4S Neuroblastoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide Phosphate
Radiation: External Beam Radiation Therapy
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Intensity-Modulated Radiation Therapy
Radiation: Iobenguane I-131
Drug: Isotretinoin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Other: Pharmacological Study
Other: Questionnaire Administration
Procedure: Therapeutic Conventional Surgery
Drug: Topotecan Hydrochloride
Drug: Vincristine Sulfate

First Posted Date: 2010-08-04

Last Posted Date: 2024-01-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 99

Registration Number: NCT01175356

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States

and more 22 locations

Autologous Transplant in HIV Patients (BMT CTN 0803)

Phase 2

Completed

Conditions: HIV
Lymphoma

Interventions: Procedure: Autologous transplant
Drug: BCNU
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan

First Posted Date: 2010-06-10

Last Posted Date: 2023-01-04

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 43

Registration Number: NCT01141712

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
University of CA, SF, San Francisco, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy